Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M.

Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.

PMID:
21809362
2.

Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G.

J Virol. 2011 Sep;85(17):8870-83. doi: 10.1128/JVI.00059-11. Epub 2011 Jun 22.

3.

Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.

Lemm JA, Leet JE, O'Boyle DR 2nd, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M.

Antimicrob Agents Chemother. 2011 Aug;55(8):3795-802. doi: 10.1128/AAC.00146-11. Epub 2011 May 16.

4.

Multifaceted roles for lipids in viral infection.

Heaton NS, Randall G.

Trends Microbiol. 2011 Jul;19(7):368-75. doi: 10.1016/j.tim.2011.03.007. Epub 2011 Apr 29. Review.

5.

Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.

Lim YS, Hwang SB.

J Biol Chem. 2011 Apr 1;286(13):11290-8. doi: 10.1074/jbc.M110.194472. Epub 2011 Feb 5.

6.

Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites.

Stefan CJ, Manford AG, Baird D, Yamada-Hanff J, Mao Y, Emr SD.

Cell. 2011 Feb 4;144(3):389-401. doi: 10.1016/j.cell.2010.12.034.

7.

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, B├╝hler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R.

Cell Host Microbe. 2011 Jan 20;9(1):32-45. doi: 10.1016/j.chom.2010.12.002.

8.

Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.

Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H.

J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22.

9.

New HCV therapies on the horizon.

Vermehren J, Sarrazin C.

Clin Microbiol Infect. 2011 Feb;17(2):122-34. doi: 10.1111/j.1469-0691.2010.03430.x. Review.

10.

Viral reorganization of the secretory pathway generates distinct organelles for RNA replication.

Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJ, Altan-Bonnet N.

Cell. 2010 May 28;141(5):799-811. doi: 10.1016/j.cell.2010.03.050.

11.

Development of novel therapies for hepatitis C.

Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA.

Antiviral Res. 2010 Apr;86(1):79-92. doi: 10.1016/j.antiviral.2010.02.003. Review.

PMID:
20417376
12.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
13.

Role of annexin A2 in the production of infectious hepatitis C virus particles.

Backes P, Quinkert D, Reiss S, Binder M, Zayas M, Rescher U, Gerke V, Bartenschlager R, Lohmann V.

J Virol. 2010 Jun;84(11):5775-89. doi: 10.1128/JVI.02343-09. Epub 2010 Mar 24.

14.

SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.

Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, Harris R, Erdmann F, Fischer G, Ribeill Y.

Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. doi: 10.1128/AAC.00660-09. Epub 2009 Nov 23.

15.

Identification of hepatitis C virus NS5A inhibitors.

Lemm JA, O'Boyle D 2nd, Liu M, Nower PT, Colonno R, Deshpande MS, Snyder LB, Martin SW, St Laurent DR, Serrano-Wu MH, Romine JL, Meanwell NA, Gao M.

J Virol. 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.

16.

Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA.

J Virol. 2009 Oct;83(19):10058-74. doi: 10.1128/JVI.02418-08. Epub 2009 Jul 15.

17.

Naturally occurring hepatitis C virus subgenomic deletion mutants replicate efficiently in Huh-7 cells and are trans-packaged in vitro to generate infectious defective particles.

Pacini L, Graziani R, Bartholomew L, De Francesco R, Paonessa G.

J Virol. 2009 Sep;83(18):9079-93. doi: 10.1128/JVI.00308-09. Epub 2009 Jul 8.

18.

Role of oxysterol binding protein in hepatitis C virus infection.

Amako Y, Sarkeshik A, Hotta H, Yates J 3rd, Siddiqui A.

J Virol. 2009 Sep;83(18):9237-46. doi: 10.1128/JVI.00958-09. Epub 2009 Jul 1.

19.

Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P(2).

Hammond GR, Schiavo G, Irvine RF.

Biochem J. 2009 Jul 29;422(1):23-35. doi: 10.1042/BJ20090428.

20.

Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication.

Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7577-82. doi: 10.1073/pnas.0902693106. Epub 2009 Apr 17.

Supplemental Content

Support Center